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INTRODUCTION
-glucan is a polysaccharide in the form of fiber that is
found in baker’s yeast, oats and barley fiber as well as medic-
inal mushrooms.  -glucan is present in natural yeast and
mushrooms mainly as  -1,3-glucan or  -1,6-glucan, and as
-1,3-glucan and  -1,4-glucan in oats and barley (Fig. 1). 
The commercial  -glucan extract is usually produced from
yeast such as baker’s yeast or Saccharomyces cerevisiae (1). In
Korea, there are many  -glucan products available on the
market, which are generally extracted from mushrooms, such
as Phellinus linteus or Sparassis crispa. 
-glucan has been evaluated with regard to its various
effects, including its immune modulating effects, anticar-
cinogenic effects, lipid lowering effects, as well as its ability
to reduce the blood sugar levels and weight. It is a type of
dietary fiber that is defined as indigestible plants carbohy-
drate.
Until recently, dietary fiber was divided into two types:
hydrosoluble and insoluble. Hydrosoluble fibers lower the
blood cholesterol level and delay the absorption of sugar, while
insoluble fibers increase the volume of the stool. However,
this categorization does not accurately represent the effects
of all fibers. For example, oat bran lowers the cholesterol lev-
els but wheat bran, which is also a hydrosoluble fiber, does
not (2). In addition, cornstarch, which is a hydrosoluble fiber,
does not lower the cholesterol levels. Moreover, while a large
number of insoluble fibers increase the quantity of stools, cel-
lulose does not. However, although their categorization sug-
gests that they should not, some hydrosoluble fibers, such
as oat bran and psyllium, increase the quantity of stools. 
The failure of the categories, hydrosoluble and insoluble,
to accurately classify the effects of various fibers has resulted
in their abandonment by the U.S. National Academy of Sci-
ences Panel on the Definition of Dietary Fiber. As a prelude
to a more accurate categorization, they have decided to exam-
ine the physiological effects of each fiber separately. The panel
determined that the effects of dietary fiber depended on the
viscosity and fermentability (3), and offered the following cat-
egories: 1) total fiber, which is the sum of dietary fiber and
functional fiber, 2) functional fibers, which are physiologi-
cally beneficial nondigestible carbohydrates. These categories
are quite broad and need to be refined considerably if they
are to be of any use in clinical settings. The panel also deter-
mined that the recommended daily intake of fiber is 38 g and
25 g for adult men and women or adolescents, respectively
(4). The aim of this study was to determine future research
directions. 
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Biomedical Issues of Dietary fiber  -Glucan
-glucan is a polysaccharide in the form of fiber and the main element of fiber in
grains such as barley, oats, yeast and mushrooms. Many studies have examined
the efficacy of  -glucan in terms of the lipid lowering effects, blood sugar reduction,
weight reduction, immune modulator, and anticarcinogenic effect. However, there
is no comprehensive review article on the biomedical issues regarding  -glucan.
The authors searched for systematic reviews and clinical experiments for each rel-
evant topic and reviewed the biomedical effects of  -glucan, for the purpose of devel-
oping research strategies for the future.
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SEARCH STRATEGY 
The effects of  -glucan in yeast or grain were examined in
various clinical settings. The relevant literature was searched
in Pubmed (1966-November to 2005). The keywords used
in the search were ‘ -glucan OR oat OR barley.’ The clini-
cal situations were classified as follows: cholesterol reduction,
blood sugar control, weight control, infection, and cancer
treatment. For each area, a search was made for systematic
reviews and clinical reports.
Among the menus of Pubmed ‘Find Systematic Reviews’
in ‘Clinical Queries’ was used to find the systematic reviews,
and a randomized controlled trial [pt] was used to locate the
randomized controlled studies. The following keywords were
also used: ‘cholesterol’ for cholesterol, ‘glucose OR diabetes
mellitus’ for sugar control, ‘weight OR obesity’ for weight
control, ‘infect* OR inflama*’ for infection and ‘neoplasm
OR cancer*’ for anticarcinogenic effect. The suitability was
determined based on the abstracts and titles of the theses.
However, many of the selected studies were not randomized
even though some of them were controlled. Therefore, some
clinical experiments, all randomized controlled studies and
systematic reviews relevant to the corresponding theme were
included. 
RESULTS OF CLINICAL EXPERIMENTS
Immune modulator 
The substances used as immune modulator drugs via injec-
tion in clinical and in vitro experiments were sizofiran (SPG,
Schizophyllum commune a  -1, 3 glucan extract, obtained
from cultured Schizophyllum commune fries), Lentinan (Len-
tinus edodes -1, 3 glucan extract), PGG-glucan (poly-[1,6]-
B-D-glucopyranosyl-1,3-B-D-glucopyranose), etc. These
substances act in the following manner: 1) promote the secre-
tion of cytokines such as TNF- and IL-1- , which bind to
-glucan receptors in macrophage and neutrophils that form
part of the nonspecific immune system, 2) suppress the sec-
retion of superoxide anion and hydrogen peroxide, and 3)
increase the activity of natural killer and lymphokine-acti-
vated killer (LAK) cells, which contribute to their germici-
dal and anticarcinogenic effects (5-10). 
Cholesterol reduction 
Recently, there has been increasing interest in the effect of
hydrosoluble dietary fiber, on lowering the blood cholesterol
concentration. There are various mechanisms by which choles-
terol is reduced by dietary fiber: binding to bile, viscosity in
the small intestine, suppression of glucose absorption, and
increased production of short-chain fatty acids (11-15).
It is unclear if these characteristics are also applicable to
most types of dietary fiber. According to meta-analysis, a daily
intake of 2-10 g of hydrosoluble fiber, such as oat bran, pectin,
psyllium and guar gum, reduces the total cholesterol and
LDL cholesterol level by a small but significant amount (reduc-
tion by 2 mg/dL per 1 g of cellulose) but does not affect the
HDL cholesterol or trigyceride level (16). However, dietary
fibers differ in viscosity and fermentability, and their effects
depend on these properties (3). Therefore, it is essential to
determine the function of all dietary fibers individually. 
There have been few systematic reviews on the effect of  -
glucan on the blood lipids. However, there are two system-
atic reviews on the effect of oats on cholesterol. Ripsin et al.
examined 10 randomized controlled studies on the effect of
meals containing oats on reducing the cholesterol level in
humans. The quantity of hydrosoluble fiber ranged from 1.1
to 7.6 g, and the meals were fed for periods ranging from 18
days to 12 weeks. When the results of these studies were meta-
analyzed, the cholesterol level was reduced by 5.9 mg/dL (95%
CI 3.3-8.4 mg/dL). The effect was high when the initial cho-
lesterol level was more than 229 mg/dL and when the quan-
tity of hydrosoluble fiber was >3 g (17). In 1999, Brown et
al. reported the results of meta-analysis on the effect of choles-
terol reduction when hydrosoluble fibers such as pectin, oat
bran, guar gum and psyllium were administered. They showed
that the cholesterol level decreased by 1.73 mg/dL per gram
of hydrosoluble fiber when 2-10 g of hydrosoluble fiber was
administered, which is not very high but significant. The
results also showed that oats, pectin and psyllium had a simi-
lar effect on the blood lipids, and did not affect the triglyc-
eride or HDL cholesterol levels. In addition, the results did
not show a difference between each research design, treatment
period, the quantity of dietary fat (16). 
Baarten et al. reported that oat bran reduces the cholesterol
level primarily because of its  -glucan content. They mixed
7.2 g of oat gum (5.8 g in  -glucan and 70 g in oat bran)
with water and administered it to 20 hypercholesterolemic
patients for four weeks. They reported that the cholesterol
level decreased by 9% in the intervention group, while there
was no difference in the placebo (maltodextrin) group. In addi-
tion, the high-density lipoprotein (HDL) and triglyceride
levels in the two groups were similar (18). In 1997, the U.S.
Food and Drug Administration (FDA) acknowledged that
hydrosoluble fiber obtained from oat (oat bran, oatmeal and
oat flour) can reduce the risk of cardiac disease (Table 1). The
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oats per day are needed to achieve significant reductions in
cholesterol. Most studies on  -glucan in oats produced pos-
itive results but some studies reported no effect (19-22). This
inconsistency can be explained in several ways: amount of  -
glucan intake, the type of diet or supplements, the molecu-
lar size of  -glucan, the baseline cholesterol level, dose-res-
ponse and long-term effect. 
Amount of  -glucan intake 
The variation in the effect might result from the differences
in intake. For example, the minimum effective intake of 3 g
a day might not be sufficient to yield significant results. In-
deed, Lovegrove et al. reported that there was no difference
in the cholesterol level when 62 patients with moderate hy-
percholesterolemia were fed either 20 g of oat bran concen-
trate (3 g of  -glucan) or wheat bran together with low-fat
milk or yogurt for eight weeks. They attributed this to the
-glucan intake being too low (19). However, Karmally et
al. reported that the total cholesterol level fell significantly
by 10.9±21.6 mg/dL (4.5%) when 152 Hispanic people
were fed either oat cereal (3 g of  -glucan per day) or corn
cereal for six weeks (23). This shows that the intake alone
cannot explain the degree to which  -glucan is effective in
reducing the cholesterol level.
Type of diets or supplements 
It was suggested that cooking or the composition of food
can explain the differences in the efficacy of  -glucan. Ker-
ckhoffs et al. fed 48 mild hyperlipidemia patients  -glucan
containing bread and biscuits (5.9 g of  -glucan) or wheat
bread and biscuit (fiber only, no  -glucan) for two weeks and
compared the results. They reported that there was no signifi-
cant difference in the cholesterol level. In contrast, when the
same quantity of  -glucan was administered to the same group
in the form of juice, the LDL cholesterol level was reduced
significantly compared with the control group. They attribut-
ed this difference to the composition of food or the process of
food preparation (24). Indeed, many studies in which  -glu-
can had been administered in bread did not report any reduc-
tion in the cholesterol level. Torronen et al. reported no dif-
ference in the lipid level when oat bran bread (11.2 g of  -
glucan) was fed to patients with mild or moderate hypercho-
lesterolemia for eight weeks (20), and Leadbetter et al. also
reported no significant difference in the cholesterol level in
40 hyperlipidemic patients given bread prepared with 30,
60 or 90 g of oat fiber was (25). However, some studies report
that feeding hyperlipidemic patients  -glucan in bread was
effective (26). 
Molecular size of  -glucan 
Differences in the molecular size of  -glucan have been
reported to have an effect. The effect of  -glucan on choles-
terol reduction can be explained in terms of the reduction of
bile reabsorption or the increase in viscosity in the small intes-
tine. If the molecular size is small, the viscosity decreases and
the effectiveness of  -glucan is reduced. Torronen et al. (20)
and Beer et al. (21) explained the ineffectiveness of the intake
of  -glucan by the small molecular size of the sample ingest-
ed. The molecular size of  -glucan used by Torronen et al.
was relatively small (370,000) and that used by Beer et al.
was 1,000,000. The molecular size of  -glucan used by Braa-
ten et al. was 1,200,000, in which  -glucan was effective in
reducing the cholesterol level (18). This suggests that the
molecular size should be at least 1,200,000 for  -glucan to
be effective. However, the molecular size of  -glucan used in
Kerckhoffs et al. study was less than 100,000 and was found
to be effective (24). Therefore, this mechanism cannot explain
all the results either. 
Subject variation of baseline cholesterol level
The variation in the baseline cholesterol level of subjects
in clinical experiments may also explain some of the differ-
ences in the results. In meta-analysis by Ripsin et al. on the
effect of oat products on reducing the cholesterol level, the
baseline cholesterol level was found to be an important fac-
tor in determining the extent cholesterol reduction (17). How-
ever, Brown et al. reported that there was virtually no rela-
tionship between the baseline cholesterol level and the reduc-
tion in cholesterol (16). Among the three clinical experiments
on patients without hyperlipidemia, two produced effective
results but one did not. Beer et al. reported no significant
difference in the total cholesterol and LDL cholesterol levels
of 14 randomly selected young men who ingested oat gum
(9 g of  -glucan per day) for 14 days (25). Robitaille et al.
reported no significant change in the cholesterol level when
34 menopausal women were fed oat bran muffins for 4 weeks
(22). In contrast, Reyna et al. reported that the lipid level in
16 well-controlled Type 2 diabetic patients was improved
more by a low-calorie diet (containing oat  -glucan instead
of fat) than by the diet recommended by the American Dia-
* FDA TALK PAPER. FDA allows whole Oat foods to make health claim
on reducing the risk of heart disease, 1997. Available at: http://www. cf-
san.fda.gov/~lrd/tpoats.html. [Accessed August 21, 2006]. 
● Soluble fiber from foods such as oat bran, as part of a diet low in
saturated fat and cholesterol, may reduce the risk of heart disease.
● The whole oat-containing food must provide at least 0.75 grams of
soluble fiber per serving. 
● The amount of soluble fiber needed for an effect on cholesterol lev-
els is about 3 grams per day. Adding whole oat flour to the list of
substances eligible to be the subject of a claim means that many
products will qualify for the claim, thus making it possible that oat-
containing products could be consumed as many as 4 times a day.
Table 1. Summary of Food and Drug Administration labeling on
oats and coronary heart disease*betes Association (27). 
As suggested by these results, most studies have found oats
to be effective in reducing the cholesterol level while some
studies have reported the opposite. This inconsistency can-
not be explained by any single factor. 
Dose response 
There are a number of other controversial issues regarding
the effect of oats on cholesterol reduction. One is the dose-
response. Meta-analysis by Ripsin et al. reported a nonlinear
dose-response in all fibers, including oats (17). 10 g and 8 g
of dietary fiber was a significant cutoff point for cholesterol
and LDL cholesterol, respectively. Davison et al. reported that
when 156 hyperlipidemia patients were fed 28, 56 or 84 g
of oatmeal or oat bran for six weeks, a significant reduction
in the LDL cholesterol level was observed only in the groups
fed 84 g of oatmeal. The level of reduction in those given 28
g, 56 g and 84 g of oat bran were 10.1%, 15.9% and 11.5%,
respectively. There appeared to be a general trend with dose
but no obvious dose-response relationship (28). 
Long-term effect 
Another controversial issue is the long-term effects. Uusi-
tupa et al. fed 36 mild or moderate hypercholesterolemic pati-
ents either oat (10.3 g of  -glucan) or wheat bran for eight
weeks and found that the total cholesterol and LDL choles-
terol levels were reduced in the oat bran group in the first
four weeks. However, there was no significant change observed
at the end of eight weeks. The cholesterol level was reduced
by 6% in the first four weeks, which is a significant reduction,
but by the end of the eight weeks the difference was only 3%,
which is not statistically significant (29, 30).
There were four articles on the effects of a barley extract
or barley diet on the lipid level. Of them, three reported a
reduction in the cholesterol level, while one reported that it
was not. McIntosh et al. reported that when 21 patients with
light hypercholesterolemia ingested 8 g of  -glucan through
a barley diet (170 g/day) for four weeks, the total cholesterol
and LDL cholesterol levels was reduced by 6% and 7%, res-
pectively, compared with the same amount of wheat food (31).
Lupton et al. reported that 79 hyperlipidemic patients fed
meals supplemented with 3 g of barley oil extract or 30 g of
barley wheat flour showed a decrease in the LDL cholesterol
level by 6.5% (barley wheat flour)-9.2% (barley oil extract)
than those given 20 g cellulose (32). Behall et al. examined
18 patients with moderate hypercholesterolemia. They showed
that three groups fed different amounts of barley showed a
linear reduction in the total cholesterol level of 14%, 17%
and 20%, respectively, compared with that of the control
group (33). However, Keogh et al. divided 18 patients with
mild hyperlipidemia into two groups and gave them  -glu-
can extracted from barley (8.1-11.9 g per day) or 6.5-9.2 g
of glucose with the same number of calories over a four-week
period. However, they did not observe any difference in the
total cholesterol level (34).
Because yeast also contains a significant amount of  -glu-
can, it can reduce the cholesterol level. However, in contrast
to barley and oats,  -glucan in yeast is likely to be less effec-
tive due to its viscosity and solubility. There has been one
study on the effect of yeast  -glucan on reducing the choles-
terol level. Nicolosi et al. gave 15 g/day of yeast  -glucan in
orange juice to 15 hypercholesterolemic patients for eight
weeks and stopped the feeding for the following four weeks.
The total cholesterol and LDL cholesterol levels decreased
by 8% in the first eight weeks but the HDL cholesterol level
increased by 16% by the end of 12 weeks. However, this clini-
cal experiment was carried out without a control group, so
it is difficult to determine the validity of the result (35). As
mentioned above, yeast  -glucan has a low viscosity and hy-
drosolubility. Therefore, if the results of the clinical experi-
ment are accepted, the effect is not likely to be caused by an
increase in viscosity in the small intestine, and should be ex-
plained by a different mechanism, such as an increase in the
production of short-chain fatty acids or decrease in the blood
insulin concentration. 
Effects on blood sugar 
There is growing interest in the relationship between dietary
fiber and diabetes. In general, if diabetic patients increase their
intake of fiber, sugar absorption can be delayed and the con-
centration of insulin will fall. For this reason, diabetic patients
are recommended to take 25-50 g of fiber per day (36). In
addition, grains such as oats and barley generally have a low
glycemic index, so they help to improve the glycometabolism.
Jennie et al. compared the results of 14 randomized controlled
trials that compared the effect of a diet with a low blood sugar
index with other usual diets on diabetic patients. They reported
that the HbA1C concentration decreased by 0.43% (95%
CI 0.13-0.73) in the groups fed a diet with a low blood sugar
index. This effect is comparable to that of acarbose and insulin
lispro regarding the reduction of the postprandial blood sugar
level (37). In general, grains, fruit, and vegetables are recom-
mended because they contain many vitamins, minerals and
fiber, which promote health. However, the American Dia-
betes Association has not yet made a judgment as to whether
a higher intake of fiber is helpful in controlling sugar, in either
people with diabetes or in the general population (38).
There have been many studies on whether  -glucan in oats
or barley is helpful for controlling blood sugar in either people
with diabetes or the general population. Most studies exam-
ined diabetic patients and reported relatively positive results.
Tapola et al. fed oats, wheat flour and glucose to 12 diabetic
patients and compared their blood sugar curves. The oat group
showed a significantly smaller area below the postprandial
blood sugar curve (39). Reyna et al. reported the results of
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ed by the American Diabetes Association and a low-calorie
diet that contained  -glucan (oat extract instead of fat) for
four weeks. They found that the  -glucan diet group showed
greater improvement in the HbA1C level (27). Jenkins et al.
fed 17 volunteer Type 2 diabetics with 50 g of white bread,
commercial oatmeal cereal (4.4 g%  -glucan),  -glucan rein-
forced morning cereal (8.1 g%  -glucan) or a  -glucan rein-
forced bar (6.5 g%  -glucan) and measured their blood sugar
level. They showed that the blood sugar of those subjects who
ate the reinforced morning cereal and reinforced bar was lower
than in those who ate the oatmeal cereal and white bread (40).
Pick et al. gave 80 Type 2 diabetics an oat bran extract or
white bread with the same number of calories for 12 weeks
and found significant differences in the area below the aver-
age blood sugar curve and the insulin peak (41). They sug-
gested that oat  -glucan fed to diabetics has positive effects
on blood sugar, HbA1C, insulin, etc. and recommended an
oat or barley diet for diabetic patients. 
Several clinical experiments have examined the differences
in the blood sugar level in conditions other than diabetes.
However, the blood sugar was not their primary concern.
Therefore, these studies may be problematic with respect to
the sample size and duration. Moreover, it may be difficult to
identify differences in the blood sugar level with fiber replace-
ment because of rapid insulin-sugar response in health sub-
jects (42). There were two randomized controlled studies that
fed  -glucan to hyperlipidemic patients, both of which report-
ed no difference in the blood glucose level of the sugar con-
trol through a  -glucan diet (31, 34). 
A number of studies have examined the differences in the
glycometabolism resulting from feeding a  -glucan diet to
the general population. Bourdon et al. reported that when
-glucan-reinforced pasta and wheat pasta were fed to 11
healthy adults, the level of insulin secretion slowed and the
increase in the blood sugar level was low (15). Li et al. report-
ed that there was no difference in blood sugar in 10 volun-
teer women fed a standard diet and barley diet for four weeks
(43). Lovergrove et al. reported no difference in the fasting
blood sugar level and insulin secretion when oat bran concen-
trate or wheat bran was fed to 62 healthy adults over an eight
week period (19). Juntunen et al. fed 20 adults with normal
glucose tolerance with rye bread, wheat bread, rye bread con-
taining oat extract, wheat pasta or white wheat bread and
observed them for eight hours. The results showed that the
blood sugar curve was similar. However, the insulin concen-
tration was lowest in those fed with the bread containing the
oat extract (44). Overall, these reports show that barley, oat,
etc. does not have any significant effect on the blood sugar
in people whose glucose tolerance is normal. 
Body weight reduction 
Another key issue is the effect on the amount of dietary
fiber intake containing  -glucan. According to the observa-
tional studies, the energy intake increases with decreasing
fiber intake (45) and the obesity rate is low in those whose
food intake contains an adequate amount of fiber (46). More-
over, an inverse correlation has been reported between the
fiber intake and weight (47) as well as with the body mass
index. The Nurse’s Health Study found that the amount of
weight gain is lower in those whose diet contains an adequate
amount of fiber (48). Most observational studies reported
that the intake of fiber reduces the level of weight gain or
the risk of obesity. However, several intervention studies did
not report a clear conclusion. At best, there are reports show-
ing that additional weight loss is achieved through the addi-
tion of fiber to a low-calorie diet (5.8 kg vs. 8.0 kg) (49) and
that the weight decreases with increasing amount of carbo-
hydrate in the diet (50). According to Howarth et al., the
effect of dietary fiber intake on weight loss is greater in obese
people, and an additional intake of 14 g of dietary fiber reduced
the energy intake by 10% and reduced the weight by 1.9 kg
over a four-month period (51). In general, the effect of fiber
on weight control is affected by the blood sugar level, which
is ultimately related to hunger, insulin secretion, gastric emp-
tying time and the intestinal hormones response (42). How-
ever, because most clinical experiments do not distinguish
between the different types of fiber, it is unclear if a specific
fiber,  -glucan in particular, is more or less effective in reduc-
ing weight.
Some clinical experiments examined the effect of  -glucan
on body weight. However, because the body weight was not
the primary concern of these studies, they did not provide spe-
cific information on weight reduction. Two studies on diabetic
patients reported that the supplementation of  -glucan thro-
ugh oats did not have any significant effect on the body weight
(17, 41). In another study, no significant effect on weight was
observed in 68 hyperlipidemic patients given a high fiber
( -glucan) diet compared with a control group (40). How-
ever, these clinical experiments focused on the changes in
blood sugar or blood lipid. Therefore, the long duration for
observing weight change could be a limitation. The incon-
sistent ground data on the effect of dietary or supplementary
-glucan on weight highlights the need for further research.
Infections 
Several laboratory and animals experiment have shown that
yeast  -glucan has a nonspecific beneficial effect on the im-
mune system (1), which may facilitate the prevention of infec-
tion or affect the progress of infections already contracted.
Four studies examined whether or not feeding yeast  -glu-
can reduces the risk of a postoperative infection. Babineau
et al. published two randomized controlled studies on the
risk of postoperative infections in patients who had under-
gone thoracic or abdominal surgery. In the two studies, PGG-
glucan was fed to 67 and 34 patients who had undergone
Dietary or Supplementary Beta Glucan  785thoracic and abdominal surgery, respectively, and reported a
significantly lower risk of postoperative infections (52, 53).
The Betafectin Gastrointestinal Study Group administered
0.5 mg/kg and 1.0 mg/kg of PGG-glucan and a placebo to
1,249 high-risk patients who had undergone gastrointestinal
surgery and reported no difference in serious infections but
showed that the risk of serious infection and death decreased
by 39% in cases other than large intestine operations. How-
ever, the clinical experiment was stopped early because there
were more frequent abnormal reactions in the PGG-glucan
administered group (54). Hamano et al. reported that, when
lentinan or a placebo was administered randomly to 25 pati-
ents who had undergone cardiopulmonary bypass surgery,
the intervention group easily recovered from the lymphocyte
hypofunction that had been observed after surgery (55). It was
also reported that the frequencies of sepsis and death decreased
significantly when a placebo or  -glucan was administered
to 41 patients who had incurred severe damage but who had
not undergone surgery (56). 
There has been little randomized research on whether  -
glucan is effective against infections. However, one study re-
ported a significant reduction in the CD4 level when didano-
sine and lentinan were administered together to 107 patients
who were HIV-positive and whose CD4 level was 200-500
cells/ L (57).
Overall, feeding yeast  -glucan to high-risk patients, such
as those who have undergone surgery, can reduce the risk of
infection. However, the precise effect is unclear. Several prob-
lems, such as controlling the reaction, remain to be solved. 
Cancer 
There have been 22 randomized controlled studies on the
use of  -glucan in cancer treatment. All were carried out in
Japan and most were published in Japanese in 2000 or before.
Among the studies, nine were on stomach cancer, of which
six used sizofirnan (SPG) and three used lentinan. Four of the
studies on stomach cancer used in patients with inoperable or
recurrent cancer (58-61), and the survival time of the subjects
was extended in all four cases. Three studies were carried out
on operable or postoperative cases (62-64) but no effect regard-
ing survival was observed except in one case of postoperative
administration. The remaining two studies did not state the
stage of stomach cancer but reported that the survival time
of the subjects was extended significantly (65, 66). 
There were six randomized controlled studies with uter-
ine cancer patients. Sizofirnan (SPG) was administered in all
cases. One study (67) was applied to patients at stage IB-IV,
and the others were applied to patients at stages II or III (68-
72). They compared the survival time, complete remission
rate, recurrence, the size of tumor, etc., with positive results
being obtained in most cases. 
In three studies,  -glucan was administered to patients
with cancers other than stomach or cervical cancer. Among
69 patients with metastatic prostate cancer, those given lenti-
nan together with hormone and anticancer chemotherapy
showed significant improvement compared with the control
group with respect to the 50% survival time and five-year
survival rate (73). Among the 33 patients with recurrent breast
cancer, those who were injected with lentinan (LNT), post-
operatively, showed slower tumor growth than the control
group (74). 
Overall, yeast glucan administered to cancer patients can
enhance the effect of anticancer chemotherapy or radiation
therapy and has positive effects on the survival and quality
of life of cancer patients. However, as stated above, most stud-
ies were carried out in one country only, Japan, and by simi-
lar research groups. Given that subjects from a single country
cannot provide an adequate sample and that similar research
groups are likely to make the same types of error (if any were
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Cholesterol: 
The results of several clinical experiments show that increased intake of beta-glucan through oat or barley generally reduces the concentration of choles-
terol. However, some clinical experiments failed to show such an effect. This inconsistency can not resolved by dosage or molecular weight of beta-
glucan, process of food preparation, and baseline cholesterol level. 
Blood sugar:
Oat or barley beta glucan may lower blood glucose in diabetic patients but mostly negative in nondiabetic. It needs to be determined whether the effect
of oat on sugar control comes from its dietary fiber or some other factors and the dose-response relation, dosage-dependency, and long-term effects
of oat need to be explained.
Body weight:
Some clinical experiments examined the effect of beta-glucan on weight. However, because their primary outcome was not weight control, they did
not provide clear and precise information regarding the effect on weight. 
Infection:
Yeast beta-glucan may reduce infection risk in high-risk patients, but it is not yet known exactly what the effect will be, and the problem of stable responses
remains to be solved.
Cancer:
Yeast beta-glucan may enhance the effect of anticancer medication or radiation therapy and have a positive effect on the survival and quality of life
of cancer patients. But most of this research was carried out in one country, Japan, and by similar research groups. It would be wise to try to confirm
the results by conducting clinical studies on the effects in other regions, and by other researchers.
Table 2. Summary of beta glucan clinical trials on various health problemsmade), it would be wise to confirm these results by other re-
searchers in other countries. 
SUMMARY
-glucan, which is a polysaccharide in the form of fiber,
is the main element of fiber in grains such as oats, barley, yeast
and mushrooms. There have been several studies on the effi-
cacy of  -glucan focusing mainly on the lipid lowering effects,
blood sugar reduction, weight reduction, immune modula-
tor, and anticarcinogenic effects (Table 2).
Cereal  -glucan and yeast  -glucan were discovered sep-
arately but were found to be similar. However, cereal  -glu-
can is mainly used to reduce the risk of cardiac diseases by
lowering the cholesterol level and controlling blood sugar.
On the other hand, yeast  -glucan is used to enhance the
immune system to fight against cancer and prevent infections.
The results of several clinical experiments show that the
increased intake of  -glucan through oat or barley generally
reduces the cholesterol level. However, some clinical experi-
ments failed to show such an effect. An attempt was made
to explain the inconsistency through the following factors:
differences in the  -glucan dose, the molecular size of  -glu-
can, the composition of food, the process of food preparation
and the initial variation in the cholesterol level. However, no
single factor can adequately explain the inconsistency. In addi-
tion, the results of research into the dose-response and long-
term effects are inconsistent.
With regard to the control of blood sugar, there have been
many positive results in diabetic patients but they have been
mainly negative in nondiabetics. With regard to barley, there
has been no randomized controlled study that observed the
blood sugar levels in diabetic patients, so it is not possible
to draw any conclusions. Moreover, there is a need to explain
whether the effect of oats on sugar control arises from its die-
tary fiber or the dose-response, dosage-dependency, and long-
term effects. Some clinical experiments have examined the
effect of  -glucan on weight. However, because their prima-
ry concern was not weight reduction, they did not provide
clear and precise information regarding the effect on weight.
A number of clinical experiments examined whether or not
-glucan in yeast or mushroom prevents an infection or can-
cer. If yeast  -glucan is given to high-risk patients, such as
those who have undergone surgery, the risk of an infection
may be reduced. However, it is not known what the effect
will be, and the problem of a stable response remains to be
solved. Yeast  -glucan it can enhance the effect of anticancer
chemotherapy or radiation therapy and have a positive effect
on the survival and quality of life of cancer patients. However,
as stated above, most of this research was carried out in only
one country, Japan, and by similar research groups. There-
fore, more study by other scientists in other countries will
be needed.
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